Hydroxyl dendrimer technology platform

Ashvattha’s technology platform consists of hydroxyl dendrimers that selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body.  Quiescent macrophage and other non-endocytosing cells do not take up the hydroxyl dendrimer.

Selective Targeting and Improved Efficacy

Animal studies have shown that compounds conjugated to Ashvattha’s hydroxyl dendrimer are significantly more efficacious than free drug alone. The improved efficacy is due to the dendrimers ability to precisely target only actively endocytosing cells such as reactive macrophages and release the drug payload only within the cell and under desired kinetics established by the size of the dendrimer and corresponding linker chemistry.

Reduced Toxicity

In numerous studies, including clinical work in healthy subjects, compounds conjugated to Asvhattha’s hydroxyl dendrimers do not bind to serum or plasma proteins, exhibit no off target toxicity, and are excreted intact in the urine.

~40 hydroxyl ends
~5-20 drug molecules per dendrimer
Tuneable drug loading
Drug conjugates = NCEs

Benefits of Hydroxyl Dendrimers

  • Selective targeting to reactive cells (cells actively endocytosing) at sites of inflammation
  • Proof of concept in 30+ animal models, 6 species including dogs and monkeys (>$30M in NIH funding)
  • No off target toxicity – no toxicity of platform at 1000 mg/kg
  • Human safety data (up to 40mg/kg) – no clinical adverse events
  • Flexible dosing and administration – oral or injectable
  • Wide range of drug payloads – small molecules, peptides, RNA/DNA
  • Tunable functionality – multiple linkers and chemistries, different size dendrimers to alter PK/distribution
  • Inexpensive to manufacture at large scale (>1kg GMP lots)